ASND Ascendis Pharma A/S Chart, History Price & Graph

Key Takeaways

• Ascendis Pharma A/S (ASND) remains in a longer-term uptrend but is experiencing a short-term pullback from recent highs near $251.
• Price action shows consolidation within a rectangle formation between support at $215 and resistance at $251.
• Short-term technical indicators signal Strong Sell, with price trading below key moving averages.
• RSI(14) at 42.15 suggests neutral to bearish momentum, while MACD shows a sell signal at -1.75.
• Pivot levels highlight immediate support at $225.23 and resistance at $227.09, with current price near $226.66.

Trend Analysis

Ascendis Pharma A/S (ASND) has exhibited a robust longer-term uptrend, recently achieving a 52-week high of $250.74 earlier in April 2026 before pulling back to around $226.66. Over the past quarter, the stock has shown strength, trading above longer-term moving averages in prior periods, but the last 30 days reflect a corrective phase with prices fluctuating between $225 and $235. Community analysis on TradingView notes an uptrend on hourly charts and a potential reverse head-and-shoulders pattern signaling bullish breakout potential, though short-term price action indicates consolidation within a broader rectangle channel.

Support and Resistance Levels

Key support levels are clustered around the daily pivot S1 at $225.23 and a broader zone near $215, aligning with the lower boundary of the rectangle formation. Resistance begins at R1 $227.09, followed by R2 $228.13 and higher levels near $234-239, with major overhead resistance at $251. Recent trading has respected these pivots, with the current price hovering near the central pivot point of $226.27. A break below $225 could test deeper support at $215, while a move above $227 may signal continuation toward upper resistance.

Moving Averages

All short- and long-term moving averages indicate sell signals, with the stock trading below its SMA5 at $227.87, SMA20 at $227.34, SMA50 at $234.67, SMA100 at $237.47, and SMA200 at $230.51. Exponential moving averages similarly show sell across MA5 ($227.63) to EMA200 ($232.40). This positioning reflects short-term weakness, though the proximity to the 200-day SMA suggests potential stabilization if support holds.

Momentum Indicators

Momentum indicators present a mixed but predominantly bearish picture. The RSI(14) stands at 42.15, in sell territory and approaching oversold conditions without reaching extreme levels. MACD(12,26) at -1.75 confirms downward momentum with a sell signal. Supporting this, Williams %R at -64.44 is in sell, ADX(14) at 45.48 indicates a strong trend (currently down), while STOCH(9,6) and CCI(14) remain neutral. Bullish notes include a buy from Ultimate Oscillator and ROC.

AI Daily Buy/Sell Signals

Tickeron’s AI Daily Buy/Sell Signals leverage artificial intelligence to scrutinize vast arrays of market data, technical indicators, and historical price patterns, generating actionable buy or sell signals for stocks like ASND. These signals draw from trend recognition, momentum shifts, and pattern matching to highlight potential entry and exit opportunities. Traders rely on them to validate chart setups, time trades amid volatility, and align with prevailing market dynamics. By automating complex analysis, the AI aids in confirming trends and reducing emotional bias in decision-making. Explore these signals to enhance your technical trading strategy.

Technical Outlook and Key Levels to Watch

Traders are monitoring the $225 support zone closely for signs of stabilization or further downside toward $215. A rebound above $227 resistance could retest $234-239, potentially resuming the uptrend if volume supports. Momentum divergence in RSI and MACD will be key, alongside price interaction with the 200-day moving average near $230-232. Watch for breakouts from the rectangle or confirmation of the reverse head-and-shoulders to gauge directional bias.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.